<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2653956&amp;fmt=gif">
Image Overlay - Windtree Announces First Patient Dosed in Phase II Study of Istaroxime in Heart Failure Patients
Image Overlay - Windtree Announces First Patient Dosed in Phase II Study of Istaroxime in Heart Failure Patients

Windtree Announces First Patient Dosed in Phase II Study of Istaroxime in Heart Failure Patients

October 7, 2020

Windtree Announces First Patient Dosed in Phase II Study of Istaroxime in Heart Failure Patients

Windtree Therapeutics, Inc. announced that it has dosed the first patient in its phase II study of istaroxime in patients experiencing early cardiogenic shock. Early cardiogenic shock is one of two developmental programs for istaroxime, with the other program targeting acute heart failure, which is supported by positive phase IIOa and IIb trial results and a FDA Fast Track designation. Fast Track programs put an extra strain on clinical trials logistics, but Yourway is prepared for such challenges.

 Back to Index
Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

Clinical Trial Supply Europe

February 24-26, 2026
Hyatt Regency, Barcelona Tower

Global Clinical Supplies Group Asia Pacific Conference

March 10-12, 2026
Conrad Seoul Hotel, South Korea

Media

Articles

Why Integration Matters in Clinical Supply Chains

Open chat
Come chat with us!
Hello! How can I help you?